Alzheimer's disease
Donepezil, Rivastigmine, Galantamine and Memantine.
Off
NICE appraisals
TA217 Donepezil, galantamine rivastigmine and memantine for the treatment of Alzheimer’s disease (March 2011)
DSU report
A review of the Eisai / Pfizer economic model on the cost-effectiveness of donepezil (PDF, 112KB) (June 2010)
A report contributing to the PenTAG report: The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatement of Alzheimer’s disease (review of TA111): a systematic review and economic model
Donepezil, rivatigmine, galantamine and memantine for the treatment of Alzheimer’s disease (PDF, 107KB)
A review of comments submitted by consultees on the reliability of economic model (March 2009) for TA111